ArticleRSC medicinal chemistry2026
Design, synthesis, and anticancer evaluation of novel pyrrole-pyrazoline/chalcone hybrids:
Mansour S Alturki, Marwa F Ahmed, Abdulaziz H Al Khzem, Mohamed S Gomaa, Mohammad Sarafroz, Nada Tawfeeq, Mashael M Alharbi, Abdulaziz K Al Mouslem, Mohammed F Aldawsari, Wajin R Alruwili and 3 more
Abstract read
In one paragraphArticle in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Mansour S AlturkiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University P. O. Box 1982 Dammam 31441 Eastern Province Kingdom of Saudi Arabia msalturki@iau.edu.sa.ORCID https://orcid.org/0000-0001-7702-9379 Marwa F AhmedDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University P.O. Box 11099 Taif 21944 Saudi Arabia marwa.farg@tu.edu.sa marwafarag80@yahoo.com ahalmalki@tu.edu.sa.
Abdulaziz H Al KhzemDepartment of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University P. O. Box 1982 Dammam 31441 Eastern Province Kingdom of Saudi Arabia msalturki@iau.edu.sa.
Mohamed S GomaaDepartment of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University P. O. Box 1982 Dammam 31441 Eastern Province Kingdom of Saudi Arabia msalturki@iau.edu.sa.ORCID https://orcid.org/0000-0003-2112-9092 Mohammad SarafrozDepartment of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University P. O. Box 1982 Dammam 31441 Eastern Province Kingdom of Saudi Arabia msalturki@iau.edu.sa.
Nada TawfeeqDepartment of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University P. O. Box 1982 Dammam 31441 Eastern Province Kingdom of Saudi Arabia msalturki@iau.edu.sa.ORCID https://orcid.org/0000-0002-9178-9021 Mashael M AlharbiDepartment of Chemistry, College of Science, King Faisal University Al-Ahsa 31982 Saudi Arabia.
Abdulaziz K Al MouslemDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University Al-Ahsa 31982 Saudi Arabia.
Mohammed F AldawsariDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University Al-kharj-11942 Saudi Arabia.
Wajin R AlruwiliCollege of Pharmacy, Imam Abdulrahman Bin Faisal University P.O. Box 1982 Dammam 31441 Saudi Arabia.
Shah Alam KhanDepartment of Pharmaceutical Chemistry, College of Pharmacy, National University of Science and Technology PO Box 620, PC 130 Muscat Oman.
Atiah H AlmalkiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Taif University P.O. Box 11099 Taif 21944 Saudi Arabia marwa.farg@tu.edu.sa marwafarag80@yahoo.com ahalmalki@tu.edu.sa.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
A novel series of pyrrole-pyrazoline/chalcone hybrids were designed, synthesized and evaluated for antiproliferative activity to target epidermal growth factor receptor (EGFR) inhibition. All the synthesized compounds were evaluated in the NCI panel of 59 human cancer cell lines, where compound 6b emerged as the most active analogue. Enzyme-binding assays confirmed its potent EGFR inhibitory activity (IC
Identifiers
PMID42051972
PMCPMC13112205
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390